News Medical

New results reinforce COPAXONE 40 mg/mL as safe and effective for RMS patients

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced up to 7-year efficacy, safety and tolerability results from the Glatiramer Acetate Low-Frequency Administration (GALA) ...
FiercePharma

Teva Receives Positive Outcome in Europe for Three-Times-a-Week COPAXONE® (Glatiramer Acetate) 40 mg/ml for the Treatment of Relapsing Forms of Multiple Sclerosis (RMS)

<0> Teva Pharmaceutical Industries Ltd.IR:United States, 215-591-8912, 215-591-3033orIsrael, 972 (3) 926-7656orPR:Israel, 972 (3) 926-7687orUnited States, 215-591-8974, 215-284-0213 </0> Teva ...
Business Insider

Momenta Pharmaceuticals Announces FDA Approval and Launch of Glatopa® (glatiramer acetate injection) 40 mg/mL

--Glatopa 40 mg/mL is a fully substitutable, AP-rated generic version of three times-a-week COPAXONE ® (glatiramer acetate injection) 40 mg/mL for the treatment of patients with relapsing forms of ...
FierceBiotech

Teva Presents New Data Which Demonstrate Reduction of Injection-Related Adverse Events with the Less Frequent Dosing of Three-times-a-week COPAXONE® (glatiramer acetate ...

<0> Teva Pharmaceutical Industries Ltd.IR:United States 215-591-8912or215-591-3033orIsrael 972 (3) 926-7656orPR:Israel 972 (3) 926-7687orUnited States 215-591-8974or215-284-0213 </0> Teva ...
Business Insider

Mylan Confirms U.S. Launch of First Generic for Copaxone® 40 mg/mL 3-Times-a-Week and Generic for Copaxone® 20 mg/mL Once-Daily

HERTFORDSHIRE, England, and PITTSBURGH, Oct. 4, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today confirmed that the company has launched in the U.S. the first Glatiramer Acetate Injection 40 ...
The Providence Journal

Mylan's ANDA for Three Times Per Week Generic Copaxone(R) 40 mg/mL Accepted for Filing by FDA

PITTSBURGH, Aug. 28, 2014 /PRNewswire/ -- Mylan Inc. today announced that its abbreviated new drug application (ANDA) for a three times per week Glatiramer Acetate Injection 40 mg/mL has been accepted ...
Pharmabiz

Teva gets Russian marketing nod for thrice a week Copaxone 40 mg/ml for RRMS treatment

Teva Pharmaceutical Industries Ltd announced that the Russian Ministry of Health has approved the Marketing Authorisation (MA) license for three-times-a-week Copaxone (glatiramer acetate injection) 40 ...
Nasdaq

Mylan, Synthon Win European Patent Office Ruling Related To Copaxone 40 Mg/ML

(RTTNews) - Mylan N.V. (MYL) said Tuesday that the company and development partner Synthon has won a significant European Patent Office ruling related to Copaxone 40 mg/mL. According to Mylan, the ...
FiercePharma

Teva Receives Positive Outcome in Europe for Three-Times-a-Week COPAXONE® (Glatiramer Acetate) 40 mg/ml for the Treatment of Relapsing Forms of Multiple Sclerosis (RMS)

MHRA and other EU Member States Issue Positive Assessment Report under the Decentralized Procedure for New, Three-Times-A-Week COPAXONE® 40 mg/ml Formulation The three-times-a-week COPAXONE® 40 mg/ml ...